EP3323422 - NEW D-CONFIGURED CATESLYTIN PEPTIDE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.04.2019 Database last updated on 31.08.2024 | |
Former | The application has been published Status updated on 20.04.2018 | Most recent event Tooltip | 26.04.2019 | Application deemed to be withdrawn | published on 29.05.2019 [2019/22] | Applicant(s) | For all designated states Université de Strasbourg 4, rue Blaise Pascal 67000 Strasbourg / FR | For all designated states Institut National de la Santé et de la Recherche Médicale 101, rue de Tolbiac 75013 Paris / FR | [2018/21] | Inventor(s) | 01 /
MARBAN, Céline 4 chemin Biberackerweg 68000 COLMAR / FR | 02 /
METZ-BOUTIGUE, Marie-Hélène 5 rue Baldung Grien 67000 STRASBOURG / FR | 03 /
LAVALLE, Philippe 128 rue des Vergers 67370 WINTZENHEIM KOCHERSBERG / FR | 04 /
SCHAAF, Pierre 5 rue de la Poudrière 67120 MOLSHEIM / FR | 05 /
HAIKEL, Youssef 52 allée de la Robertsau 67000 STRASBOURG / FR | [2018/21] | Representative(s) | Cabinet Becker et Associés 25, rue Louis le Grand 75002 Paris / FR | [2018/21] | Application number, filing date | 16306539.4 | 22.11.2016 | [2018/21] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3323422 | Date: | 23.05.2018 | Language: | EN | [2018/21] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 19.04.2017 | Classification | IPC: | A61K38/00, C07K7/08 | [2018/21] | CPC: |
C07K7/08 (EP,US);
C07K14/575 (EP);
A61K38/00 (EP,US);
A61K45/06 (US);
Y02A50/30 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/21] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | NEUES D-KONFIGURIERTES CATESLYTIN-PEPTID | [2018/21] | English: | NEW D-CONFIGURED CATESLYTIN PEPTIDE | [2018/21] | French: | NOUVEAU PEPTIDE CATESLYTIN D-CONFIGURÉ | [2018/21] | Examination procedure | 24.11.2018 | Application deemed to be withdrawn, date of legal effect [2019/22] | 11.01.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2019/22] | Fees paid | Penalty fee | Additional fee for renewal fee | 30.11.2018 | 03   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2014188373 (UNIV MANITOBA [CA], et al) [A] 1-15 * abstract *; | [A] - ASLAM R. ET AL., "Catelytin, a chromogranin A derived peptide is active against Staphylococcus aureus and resistant to degradation by its proteases", OPEN ACCESS, (20130724), vol. 8, no. 7, pages 1 - 8, XP002768893 [A] 1-15 * the whole document * | [A] - HAMAMOTO K ET AL, "ANTIMICROBIAL ACTIVITY AND STABILITY TO PROTEOLYSIS OF SMALL LINEAR CATIONIC PEPTIDES WITH D-AMINO ACID SUBSTITUTIONS", MICROBIOLOGY AND IMMUNOLOGY, CENTER FOR ACADEMIC PUBLICATIONS JAPAN|, JP, (20020101), vol. 46, no. 11, ISSN 0385-5600, pages 741 - 749, XP008053221 [A] 1-15 * the whole document * | [A] - CHRISTOPHER D. FJELL ET AL, "Designing antimicrobial peptides: form follows function", NATURE REVIEWS. DRUG DISCOVERY, GB, (20111216), doi:10.1038/nrd3591, ISSN 1474-1776, XP055317320 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1038/nrd3591 | [A] - RAMESH RATHINAKUMAR ET AL, "Broad-Spectrum Antimicrobial Peptides by Rational Combinatorial Design and High-Throughput Screening: The Importance of Interfacial Activity", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (20090610), vol. 131, no. 22, doi:10.1021/ja8093247, ISSN 0002-7863, pages 7609 - 7617, XP055012553 [A] 1-15 * page 7614, column 1, paragraph 2 - page 7614, column 2, paragraph 1 * DOI: http://dx.doi.org/10.1021/ja8093247 | by applicant | US2007184015 | WO2005006938 | - HANCOCK RE ET AL., NAT BIOTECHNOL., (2006), vol. 24, no. 12, pages 1551 - 1557 | - METZ-BOUTIGUE MH ET AL., TRENDS MICROBIOL, (2003), vol. 11, no. 12, pages 585 - 592 | - ZASLOFF M, NATURE, (2002), vol. 415, no. 6870, pages 389 - 395 | - TAUPENOT L, N. ENGL. J. MED., (2003), vol. 348, pages 1134 - 1149 | - HELLE KB ET AL., CELL. MOL. LIFE SCI., (2007), vol. 64, pages 2863 - 2886 | - ASLAM R ET AL., PLOS ONE, (2013), vol. 8, no. 7, page E68993 | - BRIOLAT J ET AL., CELL MOL LIFE SCI, (2005), vol. 62, no. 3, pages 377 - 85 | - LAMBERT ET AL., J APPL MICROBIOL, (2000), vol. 88, no. 5, pages 784 - 790 | - GOMES ET AL., INT ENDOD J., (2003), vol. 36, no. 4, pages 267 - 275 | - SAATCHI ET AL., J APPL ORAL SCI., (2014), vol. 22, no. 5, pages 356 - 365 | - BADR ET AL., INT ENDOD J., (2011), vol. 44, no. 1, pages 51 - 58 | - MALKHASSIAN ET AL., J ENDOD., (2009), vol. 35, no. 11, pages 1483 - 1490 | - PLAQUETTE ET AL., J ENDOD., (2007), vol. 33, no. 7, pages 788 - 795 | - LABBAN ET AL., DENT TRAUMATOL., (2014), vol. 30, no. 6, pages 429 - 434 | - YADLAPATI ET AL., INT ENDOD J., (2014), vol. 47, no. 8, pages 769 - 775 | - RUPAREL ET AL., J ENDOD., (2012), vol. 38, no. 10, pages 1372 - 1375 | - SCHMIDTCHEN ET AL., MOL MICROBIOL., (2002), vol. 46, no. 1, pages 157 - 168 | - HAAPASALO ET AL., INT ENDOD J., (2000), vol. 33, no. 2, pages 126 - 131 | - LAMBERT; PEARSON, J APPL MICROBIOL, (2000), vol. 88, no. 5, pages 784 - 790 |